Lb Pharmaceuticals INC Schedule 13G passive stakes

JPMorgan Chase & Co. has reported beneficial ownership of 5.2% of LB Pharmaceuticals Inc.'s common stock as of June 30, 2026.

TCG Crossover Fund II, L.P. and related entities have filed an amendment reporting a 6.4% beneficial ownership stake in LB Pharmaceuticals Inc.

Commodore Capital LP and its principals have reported a 6.8% beneficial ownership stake in LB Pharmaceuticals Inc. via a Schedule 13G filing.

Caligan Partners LP and David Johnson have disclosed a beneficial ownership of 5.0% in LB Pharmaceuticals Inc., holding 1,438,070 shares.

JPMorgan Chase & Co. has filed a Schedule 13G, reporting beneficial ownership of 4.9% of LB Pharmaceuticals Inc. common stock as of March 31, 2026.

BlackRock, Inc. has reported a 5.1% beneficial ownership stake in LB PHARMACEUTICALS INC, holding 1,277,776 shares of common stock.

BlackRock Portfolio Management LLC has filed an amended Schedule 13G, reporting a 3.8% beneficial ownership stake in LB PHARMACEUTICALS INC.

JPMorgan Chase & Co. has disclosed a 6.3% beneficial ownership stake in LB Pharmaceuticals Inc., holding over 1.6 million shares of common stock.

Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai have jointly disclosed a 5.0% beneficial ownership stake in LB Pharmaceuticals Inc.

BlackRock Portfolio Management LLC has reported a 5.9% beneficial ownership stake in LB PHARMACEUTICALS INC, held for ordinary business purposes.

RA Capital Management and its affiliates have reported a 7.5% beneficial ownership stake in LB Pharmaceuticals Inc., totaling 1,675,000 shares.

TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu have reported a passive beneficial ownership of 7.8% in LB Pharmaceuticals Inc.

Commodore Capital LP and its affiliates reported a 5.5% beneficial ownership stake in LB Pharmaceuticals Inc., totaling 1,225,000 common shares.